Frontlight ResearchEarly access
Active, not recruitingPhase 2
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Albuquerque, Baltimore, Birmingham, Brooklyn, Cincinnati, Houston, Lexington, New Haven, Palo Alto, San Antonio, and Stuart, United StatesSee the 11 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 120 people, planned
- Started
- 10 Oct 2022
- Expected to end
- 1 Oct 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- MW189
- Saline
- Record updated
- 2 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Confirmed diagnosis of spontaneous, non-traumatic ICH
- 10 mL ≤ ICH ≤ 60 mL (confirmed via diagnostic and stability CT scans utilizing volumetric assessment)
- Participants receiving anticoagulants are eligible upon reversal and stability within 24hrs after onset of ICH symptoms
- Age ≥ 18 years
- Able to receive first dose of test article ≤ 24h after onset of ICH symptoms
- NIHSS score ≥ 2 at randomization or Glasgow Coma Scale ≥ 5 at randomization
- Controlled blood pressure (systolic BP < 180 mm Hg) at randomization
- Premorbid magnetic resonance spectroscopy (mRS) of 0-2
- Has adequate venous access
- No planned surgical intervention except EVD
- Written informed consent from the patient or legally authorized representative (LAR)
Who cannot take part
- Unstable hematoma defined as > 6 mL increase as compared to previous CT volume taken at least 6 hours apart within 24 hrs after onset of ICH symptoms
- Anticipated neurosurgical evacuation by open surgery or minimally invasive surgery with or without Alteplase (EVD allowed)
- Used any chronic immunosuppressants or chronic anti-inflammatory drugs (excluding low-dose aspirin), by any route of administration within the past 7 days
- Anticipated withdrawal of life-sustaining therapies within the first week after admission
- Concomitant enrollment in another acute interventional study
- Signs of intracranial infection or emergence of a systemic infection
- Non-reversible bleeding diathesis
- In the opinion of the investigator, patient has a condition that could interfere with the proposed treatment or unacceptably increase the individual's risk by participating in the study
- Signs of liver and kidney chronic disease (i.e. creatinine >2, bilirubin > 3, receiving dialysis)
- Uncontrolled temp >38.5˚C at enrollment
- Is pregnant or lactating
- In the opinion of the investigator, patient has any contraindication to the planned study assessments
Where in United States
- University of New MexicoAlbuquerque, United States
- Johns Hopkins HospitalBaltimore, United States
- University of Alabama BirminghamBirmingham, United States
- New York University Grossman School of MedicineBrooklyn, United States
- University of CincinnatiCincinnati, United States
- University of Texas HoustonHouston, United States
- University of KentuckyLexington, United States
- Yale New Haven HospitalNew Haven, United States
- Stanford UniversityPalo Alto, United States
- University of Texas San AntonioSan Antonio, United States
- Cleveland Clinic FloridaStuart, United States
About the trial
What the trial wants to find out
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).
The 2 groups in the trial
- ExperimentalTreatment being tested
MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
Treatment: MW189
- ControlPlacebo, for comparison
Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
Treatment: Saline
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) Phase 2a Trial
- Publications
- Operationalizing a complex acute clinical trial: Lessons from the BEACH study.Journal of clinical and translational science, 2025
- Operationalizing a complex acute clinical trial: Lessons from the BEACH study.medRxiv : the preprint server for health sciences, 2025
- Clinical Trial Protocol for BEACH: A Phase 2a Study of MW189 in Patients with Acute Nontraumatic Intracerebral Hemorrhage.Neurocritical care, 2024
- Record updated
- 2 April 2026